Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs
- Published on 06/10/2024
- Reading time: 8 min.
Svenja Müller 1,2, Laura Maintz 1,2, Thomas Bieber 2,3
1
Department of Dermatology and Allergy
University Hospital Bonn
Bonn
Germany
2
Christine Kühne Center for Allergy Research and Education Davos (CK‐CARE)
Davos
Switzerland
3
Davos BioSciences
Davos
Switzerland
Abstract
Atopic dermatitis (AD) represents the most common skin disease characterized by heterogeneous endophenotypes and a high disease burden. In Europe, six new systemic therapies for AD have been approved: the biologics dupilumab (anti‐interleukin‐4 receptor (IL‐4R) α in 2017), tralokinumab (anti‐IL‐13 in 2021), lebrikizumab (anti‐IL‐13 in 2023), and the oral janus kinase (JAK) inhibitors (JAKi) targeting JAK1/2 (baricitinib in 2020...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Dermatology
Receive our newsletter to stay up to date with the latest news in Dermatology
